BioSpace News Archive

Luminex Corporation (NASDAQ: LMNX) announced that the company submitted the ARIES® MRSA Assay to the U.S. Food and Drug Administration (FDA) for clearance on Friday, June 28, 2019

Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the closing of its initial public offering of 6,900,000 shares of its common stock at a price to the public of $15.00 per share, which includes 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.

Robinson Pharma, Inc, introduces three new offerings for new qualified customers in need of contract manufacturing of health and nutrition supplements.

Merck’s supply chain and eCommerce strength will allow broader availability and accessibility of the Fire Monkey / Fire Flower product to customers

Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis and cancer, announced the appointment of Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer.

Bristol-Myers Squibb Company announced that effective July 1, 2019 it has completed its previously announced divestment of its consumer health business, UPSA, to Taisho Pharmaceutical Co., Ltd, the largest over-the-counter drug company in Japan.

New leader to rapidly build team and capabilities to scale unique stem cell-derived platelet manufacturing platform, advance core program to the clinic, and establish proof of concept for platelet-based therapeutics

Synthetic Biologics, Inc. announced receipt, on June 28, 2019, of notification from the NYSE American LLC that the Company has regained compliance with Part 10, Section 1003 of the NYSE American’s Company Guide relating to the Exchange’s continued listing requirements.

Lark DMP users decreased A1c by 1.1 points in pilot study, reducing the probability of diabetes-related complications

Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies